Benjamin Glaser

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9436889/publications.pdf

Version: 2024-02-01

211 papers	24,341 citations	14655 66 h-index	9345 143 g-index
228 all docs	228 docs citations	228 times ranked	34443 citing authors

#	Article	IF	Citations
1	Liquid biopsy reveals collateral tissue damage in cancer. JCI Insight, 2022, 7, .	5.0	32
2	Rare coding variants in 35 genes associate with circulating lipid levelsâ€"A multi-ancestry analysis of 170,000 exomes. American Journal of Human Genetics, 2022, 109, 81-96.	6.2	24
3	Universal lung epithelium DNA methylation markers for detection of lung damage in liquid biopsies. European Respiratory Journal, 2022, 60, 2103056.	6.7	10
4	B cell-derived cfDNA after primary BNT162b2 mRNA vaccination anticipates memory B cells and SARS-CoV-2 neutralizing antibodies. Med, 2022, 3, 468-480.e5.	4.4	2
5	ChIP-seq of plasma cell-free nucleosomes identifies gene expression programs of the cells of origin. Nature Biotechnology, 2021, 39, 586-598.	17.5	81
6	Biphasic dynamics of beta cell mass in a mouse model of congenital hyperinsulinism: implications for type 2 diabetes. Diabetologia, 2021, 64, 1133-1143.	6.3	12
7	Determinants of penetrance and variable expressivity in monogenic metabolic conditions across 77,184 exomes. Nature Communications, 2021, 12, 3505.	12.8	49
8	Genetic activation of Î±-cell glucokinase in mice causes enhanced glucose-suppression of glucagon secretion during normal and diabetic states. Molecular Metabolism, 2021, 49, 101193.	6.5	23
9	What is a Î² cell? â€“ Chapter I in the Human Islet Research Network (HIRN) review series. Molecular Metabolism, 2021, 53, 101323.	6.5	20
10	Remote immune processes revealed by immune-derived circulating cell-free DNA. ELife, 2021, 10, .	6.0	28
11	NCMP-01. NOVEL BIOMARKERS FOR RADIATION-INDUCED NEUROTOXICITY. Neuro-Oncology, 2021, 23, vi147-vi147.	1.2	0
12	Circulating Unmethylated Insulin DNA As a Biomarker of Human Beta Cell Death: A Multi-laboratory Assay Comparison. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 781-791.	3.6	17
13	Single-cell transcriptomics of human islet ontogeny defines the molecular basis of Î²-cell dedifferentiation in T2D. Molecular Metabolism, 2020, 42, 101057.	6.5	63
14	Evaluating drug targets through human loss-of-function genetic variation. Nature, 2020, 581, 459-464.	27.8	115
15	The mutational constraint spectrum quantified from variation in 141,456 humans. Nature, 2020, 581, 434-443.	27.8	6,140
16	A structural variation reference for medical and population genetics. Nature, 2020, 581, 444-451.	27.8	614
17	Transcript expression-aware annotation improves rare variant interpretation. Nature, 2020, 581, 452-458.	27.8	142
18	Long-term outcomes in MEN-1 patients with pancreatic neuroendocrine neoplasms: an Israeli specialist center experience. Endocrine, 2020, 68, 222-229.	2.3	9

#	Article	IF	Citations
19	Multiplexing DNA methylation markers to detect circulating cell-free DNA derived from human pancreatic Î² cells. JCI Insight, 2020, 5, .	5.0	34
20	Distinct Imprinting Signatures and Biased Differentiation of Human Androgenetic and Parthenogenetic Embryonic Stem Cells. Cell Stem Cell, 2019, 25, 419-432.e9.	11.1	31
21	Exome sequencing of 20,791Âcases of type 2 diabetes and 24,440Âcontrols. Nature, 2019, 570, 71-76.	27.8	248
22	Non-invasive detection of human cardiomyocyte death using methylation patterns of circulating DNA. Nature Communications, 2018, 9, 1443.	12.8	147
23	Beta Cell Death by Cell-free DNA and Outcome After Clinical Islet Transplantation. Transplantation, 2018, 102, 978-985.	1.0	40
24	Thyroidectomy Practice After Implementation of the 2015 American Thyroid Association Guidelines on Surgical Options for Patients With Well-Differentiated Thyroid Carcinoma. JAMA Otolaryngology - Head and Neck Surgery, 2018, 144, 427.	2.2	31
25	FOXP3 mutations causing earlyâ€onset insulinâ€requiring diabetes but without other features of immune dysregulation, polyendocrinopathy, enteropathy, Xâ€linked syndrome. Pediatric Diabetes, 2018, 19, 388-392.	2.9	25
26	Monitoring liver damage using hepatocyte-specific methylation markers in cell-free circulating DNA. JCI Insight, 2018, 3, .	5.0	94
27	Comprehensive human cell-type methylation atlas reveals origins of circulating cell-free DNA in health and disease. Nature Communications, 2018, 9, 5068.	12.8	584
28	Type 2 diabetes genetic loci informed by multi-trait associations point to disease mechanisms and subtypes: A soft clustering analysis. PLoS Medicine, 2018, 15, e1002654.	8.4	373
29	Î²-Cell DNA Damage Response Promotes Islet Inflammation in Type 1 Diabetes. Diabetes, 2018, 67, 2305-2318.	0.6	35
30	IGF-1 levels may increase paradoxically with dopamine agonist treatment for prolactinomas. Pituitary, 2018, 21, 406-413.	2.9	8
31	Insights into the genetic epidemiology of Crohn's and rare diseases in the Ashkenazi Jewish population. PLoS Genetics, 2018, 14, e1007329.	3.5	66
32	Postnatal Exocrine Pancreas Growth by Cellular Hypertrophy Correlates with a Shorter Lifespan in Mammals. Developmental Cell, 2018, 45, 726-737.e3.	7.0	32
33	Targeted demethylation at the CDKN1C/p57 locus induces human Î² cell replication. Journal of Clinical Investigation, 2018, 129, 209-214.	8.2	48
34	Beta cell heterogeneity: an evolving concept. Diabetologia, 2017, 60, 1363-1369.	6.3	40
35	A Low-Frequency Inactivating AKT2 Variant Enriched in the Finnish Population Is Associated With Fasting Insulin Levels and Type 2 Diabetes Risk. Diabetes, 2017, 66, 2019-2032.	0.6	47
36	Î²â€Cells are not uniform after allâ€”Novel insights into molecular heterogeneity of insulinâ€secreting cells. Diabetes, Obesity and Metabolism, 2017, 19, 147-152.	4.4	24

#	Article	IF	Citations
37	Pancreatic Î²-Cells Express the Fetal Islet Hormone Gastrin in Rodent and Human Diabetes. Diabetes, 2017, 66, 426-436.	0.6	47
38	Sequence data and association statistics from 12,940 type 2 diabetes cases and controls. Scientific Data, 2017, 4, 170179.	5.3	31
39	Metabolic Stress and Compromised Identity of Pancreatic Beta Cells. Frontiers in Genetics, 2017, 08, 21.	2.3	120
40	PAX6 maintains Î² cell identity by repressing genes of alternative islet cell types. Journal of Clinical Investigation, 2016, 127, 230-243.	8.2	126
41	The genetic architecture of type 2 diabetes. Nature, 2016, 536, 41-47.	27.8	952
42	Dynamical compensation in physiological circuits. Molecular Systems Biology, 2016, 12, 886.	7.2	67
43	Diagnosis of ABCC8 congenital hyperinsulinism of infancy in a 20 year-old man evaluated for factitious hypoglycemia.. Journal of Clinical Endocrinology and Metabolism, 2016, 102, jc.2016-3254.	3.6	10
44	Identification of a G-Protein Subunit-Î±11 Gain-of-Function Mutation, Val340Met, in a Family With Autosomal Dominant Hypocalcemia Type 2 (ADH2). Journal of Bone and Mineral Research, 2016, 31, 1207-1214.	2.8	36
45	Hyperglycaemia induces metabolic dysfunction and glycogen accumulation in pancreatic Î²-cells. Nature Communications, 2016, 7, 13496.	12.8	90
46	Effects of ageing and senescence on pancreatic Î²â€cell function. Diabetes, Obesity and Metabolism, 2016, 18, 58-62.	4.4	57
47	Insulin receptor alternative splicing is regulated by insulin signaling and modulates beta cell survival. Scientific Reports, 2016, 6, 31222.	3.3	59
48	Abrogation of Autophagy by Chloroquine Alone or in Combination with mTOR Inhibitors Induces Apoptosis in Neuroendocrine Tumor Cells. Neuroendocrinology, 2016, 103, 724-737.	2.5	21
49	The Genetic Program of Pancreatic Î²-Cell Replication In Vivo. Diabetes, 2016, 65, 2081-2093.	0.6	66
50	Identification of tissue-specific cell death using methylation patterns of circulating DNA. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E1826-34.	7.1	492
51	p16Ink4a-induced senescence of pancreatic beta cells enhances insulin secretion. Nature Medicine, 2016, 22, 412-420.	30.7	252
52	Weaning Triggers a Maturation Step of Pancreatic Î² Cells. Developmental Cell, 2015, 33, 238-239.	7.0	2
53	Loss of Liver Kinase B1 (LKB1) in Beta Cells Enhances Glucose-stimulated Insulin Secretion Despite Profound Mitochondrial Defects. Journal of Biological Chemistry, 2015, 290, 20934-20946.	3.4	36
54	Weaning Triggers a Maturation Step of Pancreatic Î² Cells. Developmental Cell, 2015, 32, 535-545.	7.0	120

#	Article	IF	Citations
55	Safety and Efficacy of Oral Octreotide in Acromegaly: Results of a Multicenter Phase III Trial. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 1699-1708.	3.6	144
56	Premature aging of leukocyte DNA methylation is associated with type 2 diabetes prevalence. Clinical Epigenetics, 2015, 7, 35.	4.1	34
57	Aging-Dependent Demethylation of Regulatory Elements Correlates with Chromatin State and Improved Î² Cell Function. Cell Metabolism, 2015, 22, 619-632.	16.2	172
58	G0-G1 Transition and the Restriction Point in Pancreatic Î²-Cells In Vivo. Diabetes, 2014, 63, 578-584.	0.6	27
59	Disrupting Mitochondrialâ€“Nuclear Coevolution Affects OXPHOS Complex I Integrity and Impacts Human Health. Genome Biology and Evolution, 2014, 6, 2665-2680.	2.5	68
60	Loss-of-function mutations in SLC30A8 protect against type 2 diabetes. Nature Genetics, 2014, 46, 357-363.	21.4	428
61	Type 2 Diabetes and Congenital Hyperinsulinism Cause DNA Double-Strand Breaks and p53 Activity in Î² Cells. Cell Metabolism, 2014, 19, 109-121.	16.2	123
62	Targeting the cell cycle inhibitor p57Kip2 promotes adult human Î² cell replication. Journal of Clinical Investigation, 2014, 124, 670-674.	8.2	53
63	Systemic Regulation of the Age-Related Decline of Pancreatic Î²-Cell Replication. Diabetes, 2013, 62, 2843-2848.	0.6	112
64	The Plastic Pancreas. Developmental Cell, 2013, 26, 3-7.	7.0	82
65	Systemic regulation of the age-related decline of pancreatic Î²-cell replication. Diabetes 2013;62:2843â€“2848. Diabetes, 2013, 62, 3300-3300.	0.6	3
66	Beta-Cell Dedifferentiation and Type 2 Diabetes. New England Journal of Medicine, 2013, 368, 572-573.	27.0	77
67	Identification of a SIRT1 Mutation in a Family with Type 1 Diabetes. Cell Metabolism, 2013, 17, 448-455.	16.2	103
68	Gastrin: A Distinct Fate of Neurogenin3 Positive Progenitor Cells in the Embryonic Pancreas. PLoS ONE, 2013, 8, e70397.	2.5	43
69	The Expression of the Beta Cell-Derived Autoimmune Ligand for the Killer Receptor Nkp46 Is Attenuated in Type 2 Diabetes. PLoS ONE, 2013, 8, e74033.	2.5	14
70	Relative Expression of a Dominant Mutated ABCC8 Allele Determines the Clinical Manifestation of Congenital Hyperinsulinism. Diabetes, 2012, 61, 258-263.	0.6	15
71	Ga-68 DOTA-NOC Uptake in the Pancreas. Clinical Nuclear Medicine, 2012, 37, 57-62.	1.3	36
72	Genome-wide survey reveals predisposing diabetes type 2-related DNA methylation variations in human peripheral blood. Human Molecular Genetics, 2012, 21, 371-383.	2.9	317

#	Article	IF	Citations
73	Glucose metabolism: key endogenous regulator of Î²â€cell replication and survival. Diabetes, Obesity and Metabolism, 2012, 14, 101-108.	4.4	32
74	Pancreatic Beta Cells in Very Old Mice Retain Capacity for Compensatory Proliferation. Journal of Biological Chemistry, 2012, 287, 27407-27414.	3.4	59
75	Control of Pancreatic Î² Cell Regeneration by Glucose Metabolism. Cell Metabolism, 2011, 13, 440-449.	16.2	266
76	ABCC8 mutation allele frequency in the Ashkenazi Jewish population and risk of focal hyperinsulinemic hypoglycemia. Genetics in Medicine, 2011, 13, 891-894.	2.4	25
77	Glucagonoma and the glucagonoma syndrome - cumulative experience with an elusive endocrine tumour. Clinical Endocrinology, 2011, 74, 593-598.	2.4	109
78	68Ga-DOTA-NOC PET/CT Imaging of Neuroendocrine Tumors: Comparison with 111In-DTPA-Octreotide (OctreoScanÂ®). Molecular Imaging and Biology, 2011, 13, 583-593.	2.6	131
79	Glucose Regulates Cyclin D2 Expression in Quiescent and Replicating Pancreatic Î²-Cells Through Glycolysis and Calcium Channels. Endocrinology, 2011, 152, 2589-2598.	2.8	58
80	Recognition and Killing of Human and Murine Pancreatic Î² Cells by the NK Receptor NKp46. Journal of Immunology, 2011, 187, 3096-3103.	0.8	53
81	Lessons in human biology from a monogenic pancreatic Î² cell disease. Journal of Clinical Investigation, 2011, 121, 3821-3825.	8.2	8
82	Predicting Diabetic Nephropathy Using a Multifactorial Genetic Model. PLoS ONE, 2011, 6, e18743.	2.5	29
83	Single pancreatic beta cells co-express multiple islet hormone genes in mice. Diabetologia, 2010, 53, 128-138.	6.3	58
84	Effects of Moderate Intensity Glycemic Control After Cardiac Surgery. Annals of Thoracic Surgery, 2010, 90, 1825-1832.	1.3	43
85	Detailed Investigation of the Role of Common and Low-Frequency WFS1 Variants in Type 2 Diabetes Risk. Diabetes, 2010, 59, 741-746.	0.6	34
86	Large Islets, Beta-Cell Proliferation, and a Glucokinase Mutation. New England Journal of Medicine, 2010, 362, 1348-1350.	27.0	81
87	Identification of a Heterozygous Sulfonylurea Receptor 1 Mutation that Exerts a Strong Dominant-Negative Effect on KATP Channel Response to MgADP. Biophysical Journal, 2010, 98, 699a.	0.5	0
88	Gene-Gene Interactions Lead to Higher Risk for Development of Type 2 Diabetes in an Ashkenazi Jewish Population. PLoS ONE, 2010, 5, e9903.	2.5	52
89	Genetic analysis of complex disease--a roadmap to understanding or a colossal waste of money. Pediatric Endocrinology Reviews, 2010, 7, 258-65.	1.2	8
90	Preliminary evidence that a functional polymorphism in type 1 deiodinase is associated with enhanced potentiation of the antidepressant effect of sertraline by triiodothyronine. Journal of Affective Disorders, 2009, 116, 113-116.	4.1	45

#	Article	IF	Citations
91	Parental diabetes status reveals association of mitochondrial DNA haplogroup J1 with type 2 diabetes. BMC Medical Genetics, 2009, 10, 60.	2.1	33
92	Impact of polymorphisms in WFS1 on prediabetic phenotypes in a population-based sample of middle-aged people with normal and abnormal glucose regulation. Diabetologia, 2008, 51, 1646-1652.	6.3	44
93	Differences in mtDNA haplogroup distribution among 3 Jewish populations alter susceptibility to T2DM complications. BMC Genomics, 2008, 9, 198.	2.8	35
94	The H syndrome: A genodermatosis characterized by indurated, hyperpigmented, and hypertrichotic skin with systemic manifestations. Journal of the American Academy of Dermatology, 2008, 59, 79-85.	1.2	117
95	Novel De Novo Mutation in Sulfonylurea Receptor 1 Presenting as Hyperinsulinism in Infancy Followed by Overt Diabetes in Early Adolescence. Diabetes, 2008, 57, 1935-1940.	0.6	49
96	Population-Specific Risk of Type 2 Diabetes Conferred by HNF4A P2 Promoter Variants: A Lesson for Replication Studies. Diabetes, 2008, 57, 3161-3165.	0.6	37
97	Insulin Mutations in Diabetes. Diabetes, 2008, 57, 799-800.	0.6	15
98	Long-acting somatostatin analogues are an effective treatment for type 1 gastric carcinoid tumours. European Journal of Endocrinology, 2008, 159, 475-482.	3.7	69
99	Post Genome-Wide Association Studies of Novel Genes Associated with Type 2 Diabetes Show Gene-Gene Interaction and High Predictive Value. PLoS ONE, 2008, 3, e2031.	2.5	132
100	In-hospital treatment of hyperglycemia: effects of intensified subcutaneous insulin treatment. Current Medical Research and Opinion, 2007, 23, 757-765.	1.9	11
101	Î²-Cell Mitochondria Exhibit Membrane Potential Heterogeneity That Can Be Altered by Stimulatory or Toxic Fuel Levels. Diabetes, 2007, 56, 2569-2578.	0.6	104
102	Long-term neurodevelopmental outcome in conservatively treated congenital hyperinsulinism. European Journal of Endocrinology, 2007, 157, 491-497.	3.7	57
103	Combined Treatment With Sertraline and Liothyronine in Major Depression. Archives of General Psychiatry, 2007, 64, 679.	12.3	97
104	Common variants in WFS1 confer risk of type 2 diabetes. Nature Genetics, 2007, 39, 951-953.	21.4	333
105	Ashkenazi Jewish mtDNA haplogroup distribution varies among distinct subpopulations: lessons of population substructure in a closed group. European Journal of Human Genetics, 2007, 15, 498-500.	2.8	27
106	Sulfonylurea-Responsive Diabetes in Childhood. Journal of Pediatrics, 2007, 150, 553-555.	1.8	15
107	Growth hormone reserve in adult beta thalassemia patients. Endocrine, 2007, 31, 33-37.	2.2	15
108	Type 2 Diabetes: Hypoinsulinism, Hyperinsulinism, or Both?. PLoS Medicine, 2007, 4, e148.	8.4	18

#	Article	IF	Citations
109	Pendred Syndrome. , 2006, 11, 154-168.		0
110	p57Kip2 (cdkn1c): sequence, splice variants and unique temporal and spatial expression pattern in the rat pancreas. Laboratory Investigation, 2005, 85, 364-375.	3.7	14
111	A novel splice-site mutation in ECM-1 gene in a consanguineous family with lipoid proteinosis. Experimental Dermatology, 2005, 14, 891-897.	2.9	27
112	CT of the Ear in Pendred Syndrome. Radiology, 2005, 235, 537-540.	7.3	40
113	Hyperinsulinemic Hypoglycemia in Beckwith-Wiedemann Syndrome due to Defects in the Function of Pancreatic Î²-Cell Adenosine Triphosphate-Sensitive Potassium Channels. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 4376-4382.	3.6	63
114	Germline fumarate hydratase mutations and evidence for a founder mutation underlying multiple cutaneous and uterine leiomyomata. Journal of the American Academy of Dermatology, 2005, 52, 410-416.	1.2	53
115	Malaria and asymptomatic parasitaemia in Gabonese infants under the age of 3 months. Acta Tropica, 2005, 95, 81-85.	2.0	21
116	Rapid and Sustained Relief from the Symptoms of Carcinoid Syndrome: Results from an Open 6-Month Study of the 28-Day Prolonged-Release Formulation of Lanreotide. Neuroendocrinology, 2004, 80, 244-251.	2.5	152
117	Glibenclamide Treatment in Permanent Neonatal Diabetes Mellitus due to an Activating Mutation in Kir6.2. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 5504-5507.	3.6	186
118	Hyperinsulinism of Infancy: Novel ABCC8 and KCNJ11 Mutations and Evidence for Additional Locus Heterogeneity. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 6224-6234.	3.6	77
119	A single-nucleotide polymorphism in the RAD51 gene modifies breast cancer risk in BRCA2 carriers, but not in BRCA1 carriers or noncarriers. British Journal of Cancer, 2004, 90, 2002-2005.	6.4	99
120	Polyglutamine repeat length in theAIB1 gene modifies breast cancer susceptibility inBRCA1 carriers. International Journal of Cancer, 2004, 108, 399-403.	5.1	41
121	A Common Polymorphism in the Upstream Promoter Region of the Hepatocyte Nuclear Factor-4Î± Gene on Chromosome 20q Is Associated With Type 2 Diabetes and Appears to Contribute to the Evidence for Linkage in an Ashkenazi Jewish Population. Diabetes, 2004, 53, 1134-1140.	0.6	213
122	Germline Fumarate Hydratase Mutations in Families with Multiple Cutaneous and Uterine Leiomyomata. Journal of Investigative Dermatology, 2003, 121, 741-744.	0.7	61
123	Dominant SUR1 mutation causing autosomal dominant type 2 diabetes. Lancet, The, 2003, 361, 272-273.	13.7	9
124	Polymorphisms of the HDL Receptor Gene Associated with HDL Cholesterol Levels in Diabetic Kindred from Three Populations. Human Heredity, 2003, 55, 163-170.	0.8	29
125	Compound Heterozygosity for the Common Sulfonylurea Receptor Mutations Can Cause Mild Diazoxide-Sensitive Hyperinsulinism. Clinical Pediatrics, 2002, 41, 183-186.	0.8	23
126	Reproducibility of Glucose Measurements Using the Glucose Sensor. Diabetes Care, 2002, 25, 1185-1191.	8.6	123

#	Article	IF	Citations
127	Searching for Type 2 Diabetes Genes on Chromosome 20. Diabetes, 2002, 51, S308-S315.	0.6	26
128	Uncontrolled insulin secretion from a childhood pancreatic beta-cell adenoma is not due to the functional loss of ATP-sensitive potassium channels.. Endocrine-Related Cancer, 2002, 9, 221-226.	3.1	7
129	Evidence for Extensive Locus Heterogeneity in Naxos Disease. Journal of Investigative Dermatology, 2002, 118, 557-560.	0.7	33
130	CAG and GGC repeat polymorphisms in the androgen receptor gene and breast cancer susceptibility in BRCA1/2 carriers and non-carriers. British Journal of Cancer, 2001, 85, 36-40.	6.4	64
131	Missense polymorphism in the human carboxypeptidase E gene alters enzymatic activity. Human Mutation, 2001, 18, 120-131.	2.5	75
132	Isolation and characterization of the human AKT1 gene, identification of 13 single nucleotide polymorphisms (SNPs), and their lack of association with Type II diabetes. Diabetologia, 2001, 44, 910-913.	6.3	16
133	p57KIP2 Expression in Normal Islet Cells and in Hyperinsulinism of Infancy. Diabetes, 2001, 50, 2763-2769.	0.6	92
134	Hyperinsulinism of Infancy: The Regulated Release of Insulin by KATP Channel–Independent Pathways. Diabetes, 2001, 50, 329-339.	0.6	60
135	Dysregulation of Insulin Secretion in Children With Congenital Hyperinsulinism due to Sulfonylurea Receptor Mutations. Diabetes, 2001, 50, 322-328.	0.6	129
136	A Genome Scan for Type 2 Diabetes Susceptibility Loci in a Genetically Isolated Population. Diabetes, 2001, 50, 681-685.	0.6	135
137	Monilethrix: Mutational Hotspot in the Helix Termination Motif of the Human Hair Basic Keratin 6. Human Heredity, 2000, 50, 325-330.	0.8	32
138	A recessive contiguous gene deletion causing infantile hyperinsulinism, enteropathy and deafness identifies the Usher type 1C gene. Nature Genetics, 2000, 26, 56-60.	21.4	307
139	Hyperinsulinism of the newborn. Seminars in Perinatology, 2000, 24, 150-163.	2.5	37
140	Genetics of neonatal hyperinsulinism. Archives of Disease in Childhood: Fetal and Neonatal Edition, 2000, 82, 79F-86.	2.8	184
141	The role of ATP-sensitive K+ channels in familial hyperinsulinism. , 2000, , 299-325.		3
142	Beta-cell proliferation and apoptosis in the developing normal human pancreas and in hyperinsulinism of infancy.. Diabetes, 2000, 49, 1325-1333.	0.6	369
143	Molecular basis and characterization of the hyperinsulinism/hyperammonemia syndrome: predominance of mutations in exons 11 and 12 of the glutamate dehydrogenase gene. HI/HA Contributing Investigators.. Diabetes, 2000, 49, 667-673.	0.6	162
144	Calcium-stimulated insulin secretion in diffuse and focal forms of congenital hyperinsulinism. Journal of Pediatrics, 2000, 137, 239-246.	1.8	56

#	Article	IF	Citations
145	Hyperinsulinism caused by paternal-specific inheritance of a recessive mutation in the sulfonylurea-receptor gene. Diabetes, 1999, 48, 1652-1657.	0.6	79
146	Early intensive insulin treatment for induction of longâ€term glycaemic control in type 2 diabetes. Diabetes, Obesity and Metabolism, 1999, 1, 67-74.	4.4	36
147	Intragenic single nucleotide polymorphism haplotype analysis of SUR1 mutations in familial hyperinsulinism. , 1999, 14, 23-29.		17
148	Neonatal Hyperinsulinism. Trends in Endocrinology and Metabolism, 1999, 10, 55-61.	7.1	29
149	Somatostatin Receptor Scintigraphy for Early Detection of Regional and Distant Metastases of Medullary Carcinoma of the Thyroid. Clinical Nuclear Medicine, 1999, 24, 256-260.	1.3	28
150	Mapping of the human insulin receptor substrate-2 gene, identification of a linked polymorphic marker and linkage analysis in families with Type II diabetes: no evidence for a major susceptibility role. Diabetologia, 1998, 41, 1389-1391.	6.3	29
151	Clinical and molecular heterogeneity of familial hyperinsulinism. Journal of Pediatrics, 1998, 133, 801-803.	1.8	10
152	Familial hyperinsulinism with apparent autosomal dominant inheritance: Clinical and genetic differences from the autosomal recessive variant. Journal of Pediatrics, 1998, 132, 9-14.	1.8	77
153	Pancreatic beta-cell glucokinase: closing the gap between theoretical concepts and experimental realities.. Diabetes, 1998, 47, 307-315.	0.6	306
154	Familial Hyperinsulinism Caused by an Activating Glucokinase Mutation. New England Journal of Medicine, 1998, 338, 226-230.	27.0	537
155	Genetic Heterogeneity in Familial Hyperinsulinism. Human Molecular Genetics, 1998, 7, 1119-1128.	2.9	116
156	Hepatocyte nuclear factor 1alpha coding mutations are an uncommon contributor to early-onset type 2 diabetes in Ashkenazi Jews. Diabetes, 1998, 47, 967-969.	0.6	16
157	Somatostatin-Receptor Scintigraphy in the Management of Gastroenteropancreatic Tumors. American Journal of Gastroenterology, 1998, 93, 66-70.	0.4	69
158	Hyperinsulinism: molecular aetiology of focal disease. Archives of Disease in Childhood, 1998, 79, 445-447.	1.9	62
159	Functional analyses of novel mutations in the sulfonylurea receptor 1 associated with persistent hyperinsulinemic hypoglycemia of infancy.. Diabetes, 1998, 47, 1145-1151.	0.6	148
160	Isolation and characterization of the human PAX4 gene. Diabetes, 1998, 47, 1650-1653.	0.6	15
161	Induction of Long-Term Glycemic Control in Newly Diagnosed Type 2 Diabetic Patients by Transient Intensive Insulin Treatment. Diabetes Care, 1997, 20, 1353-1356.	8.6	245
162	Pendred syndrome is caused by mutations in a putative sulphate transporter gene (PDS). Nature Genetics, 1997, 17, 411-422.	21.4	1,081

#	Article	IF	Citations
163	Genetics of NIDDM in France: studies with 19 candidate genes in affected sib pairs. Diabetes, 1997, 46, 1062-1068.	0.6	21
164	Adenosine Diphosphate as an Intracellular Regulator of Insulin Secretion. Science, 1996, 272, 1785-1787.	12.6	494
165	Normal proinsulin processing despite beta-cell dysfunction in persistent hyperinsulinaemic hypoglycaemia of infancy (nesidioblastosis). Diabetologia, 1996, 39, 1338-1344.	6.3	11
166	Pendred syndrome maps to chromosome 7q21-34 and is caused by an intrinsic defect in thyroid iodine organification. Nature Genetics, 1996, 12, 424-426.	21.4	159
167	Mutations in the sulonylurea receptor gene are associated with familial hyperinsulinism in Ashkenazi Jews. Human Molecular Genetics, 1996, 5, 1813-1822.	2.9	233
168	Studies in Psychoneuroimmunology: Psychological, Immunological, and Neuroendocrinological Parameters in Israeli Civilians during and after a Period of Scud Missile Attacks. Behavioral Medicine, 1996, 22, 5-14.	1.9	34
169	Recombinant mapping of the familial hyperinsulinism gene to an 0.8 cM region on chromosome 11p15.1 and demonstration of a founder effect in Ashkenazi Jews. Human Molecular Genetics, 1995, 4, 2187-2188.	2.9	0
170	Hyperinsulinemic hypoglycemia of infancy (nesidioblastosis) in clinical remission: high incidence of diabetes mellitus and persistent beta-cell dysfunction at long-term follow-up. Journal of Clinical Endocrinology and Metabolism, 1995, 80, 386-392.	3.6	103
171	Familial hyperinsulinism maps to chromosome 11p14â€“15.1, 30 cM centromeric to the insulin gene. Nature Genetics, 1994, 7, 185-188.	21.4	115
172	Improvement of sleep apnoea due to acromegaly during shortâ€term treatment with octreotide. Journal of Internal Medicine, 1994, 236, 231-235.	6.0	20
173	Gallbladder Visualization With In-111 Labeled Octreotide. Clinical Nuclear Medicine, 1994, 19, 133-135.	1.3	13
174	Somatostatin-Receptor Imaging of Medullary Thyroid Carcinoma. Clinical Nuclear Medicine, 1994, 19, 416-421.	1.3	19
175	Recurrence-associated mortality in patients with differentiated thyroid carcinoma. Journal of Surgical Oncology, 1993, 52, 164-168.	1.7	13
176	Cross-sectional and longitudinal study of the pituitary-thyroid axis in patients with thalassaemia major. Clinical Endocrinology, 1993, 38, 55-61.	2.4	42
177	Persistent hyperinsulinemic hypoglycemia of infancy: Long-term octreotide treatment without pancreatectomy. Journal of Pediatrics, 1993, 123, 644-650.	1.8	147
178	TSH Producing Pituitary Tumor:. Hormone and Metabolic Research, 1992, 24, 34-38.	1.5	6
179	Glycosylated Serum Protein Levels Assayed With Highly Sensitive Immunoradiometric Assay Accurately Reflect Glycemic Control of Diabetic Patients. Diabetes Care, 1992, 15, 645-650.	8.6	8
180	Growth-Hormone-Binding Protein in Patients with Acromegaly. Hormone Research, 1992, 37, 205-211.	1.8	30

#	Article	IF	Citations
181	Effect of 6-month gliclazide treatment on insulin release and sensitivity to endogenous insulin in NIDDM: Role of initial continuous subcutaneous insulin infusion-induced normoglycemia. American Journal of Medicine, 1991, 90, S37-S45.	1.5	18
182	Effect of 6 months' gliclazide treatment on insulin release and sensitivity to endogenous insulin in NIDDM: role of initial CSII-induced normoglycemia. Diabetes Research and Clinical Practice, 1991, 14, S69-S78.	2.8	3
183	Unusual Causes of I-131 Metaiodobenzylguanidine Uptake in Non-neural Crest Tissue. Clinical Nuclear Medicine, 1991, 16, 239-242.	1.3	24
184	Sebum Measurements for Rapid Identification of Hyperandrogenism Due to an Ovarian Leydig Cell Tumor. International Journal of Dermatology, 1991, 30, 276-277.	1.0	7
185	Long-Term Treatment with the Somatostatin Analogue SMS 201â€“995: Alternative to Pancreatectomy in Persistent Hyperinsulinaemic Hypoglycaemia of Infancy. Digestion, 1990, 45, 27-35.	2.3	58
186	Regulation of insulin release in persistent hyperinsulinaemic hypoglycaemia of infancy studied in long-term culture of pancreatic tissue. Diabetologia, 1990, 33, 482-488.	6.3	29
187	Persistent hyperinsulinemic hypoglycemia of infancy (â€œnesidioblastosisâ€): Autosomal recessive inheritance in 7 pedigrees. American Journal of Medical Genetics Part A, 1990, 37, 511-515.	2.4	37
188	PERSISTENT HYPERINSULINAEMIC HYPOGLYCAEMIA OF INFANCY: LONGâ€TERM TREATMENT WITH THE SOMATOSTATIN ANALOGUE SANDOSTATINâ€. Clinical Endocrinology, 1989, 31, 71-80.	2.4	48
189	Gastrin-producing ovarian cystadenocarcinoma: Sensitivity to secretin and SMS 201-995. Gastroenterology, 1989, 97, 464-467.	1.3	21
190	Lipid Cell Tumor of the Ovary: Steroid Hormone Secretory Pattern and Localization Using 75Se-Selenomethylcholesterol. Gynecologic and Obstetric Investigation, 1989, 27, 110-112.	1.6	3
191	Effects of Secretin on the Normal and PathologicalÎ²-Cell*. Journal of Clinical Endocrinology and Metabolism, 1988, 66, 1138-1143.	3.6	29
192	Pancreatic Polypeptide Response to Secretin in Obesity: Effects of Glucose Intolerance. Hormone and Metabolic Research, 1988, 20, 288-292.	1.5	63
193	Improved beta-cell function after intensive insulin treatment in severe non-insulin-dependent diabetes. European Journal of Endocrinology, 1988, 118, 365-373.	3.7	86
194	Toxic Multinodular Goiter: A Variant of Autoimmune Hyperthyroidism*. Journal of Clinical Endocrinology and Metabolism, 1987, 65, 659-664.	3.6	50
195	THYROTROPHIN RECEPTOR BLOCKING ANTIBODIES: INCIDENCE, CHARACTERIZATION AND IN-VITRO SYNTHESIS. Clinical Endocrinology, 1987, 27, 409-421.	2.4	66
196	Magnetic resonance imaging of the pituitary gland. Clinical Radiology, 1986, 37, 9-14.	1.1	18
197	L-Thyroxine-Induced Leukopenia in a Patient with Hashimoto's Disease: Involvement of Suppressor-Cytotoxic T cells. Journal of Clinical Endocrinology and Metabolism, 1985, 61, 980-982.	3.6	2
198	Leydig-cell tumor of the ovary: Visualization using 131I-19-iodocholesterol scintigraphy. European Journal of Nuclear Medicine and Molecular Imaging, 1985, 11, 13-16.	2.1	3

#	Article	IF	Citations
199	Cellular immune functions in patients with primary hyperparathyroidism: Effects of histamine and cimetidine. Immunopharmacology, 1985, 9, 81-86.	2.0	0
200	Do cyclic AMP concentrations in saliva reflect PTH biologic activity?. Metabolism: Clinical and Experimental, 1985, 34, 505-508.	3.4	2
201	Effect of Acute Cimetidine Administration on Indices of Parathyroid Hormone Action in Healthy Subjects and Patients with Primary and Secondary Hyperparathyroidism. Journal of Clinical Endocrinology and Metabolism, 1984, 59, 993-997.	3.6	3
202	SODIUM VALPROATE AND METYRAPONE FOR PITUITARY-DEPENDENT CUSHING'S DISEASE. Lancet, The, 1984, 324, 640.	13.7	8
203	Secretion of pancreatic polypeptide in man in response to beef ingestion is mediated in part by an extravagal cholinergic mechanism. Metabolism: Clinical and Experimental, 1983, 32, 57-61.	3.4	16
204	Sex Difference in the Sensitivity of the Human Pancreatic Polypeptide Cell to Autonomic Nervous Stimulation in Man*. Journal of Clinical Endocrinology and Metabolism, 1983, 56, 21-25.	3.6	6
205	A Spot Sample Test for the Estimation of Urinary or Nephrogenous cAMP in the Evaluation of Parathyroid Function. Nephron, 1983, 35, 264-266.	1.8	2
206	Percutaneous Transhepatic Venous Sampling of Gastrin. New England Journal of Medicine, 1982, 307, 293-297.	27.0	72
207	A New Syndrome of Symptomatic Cutaneous Mastocytoma Producing Vasoactive Intestinal Polypeptide. Gastroenterology, 1982, 82, 963-967.	1.3	32
208	Gastrointestinal/pancreatic hormone concentrations in the portal venous system of nine patients with organic hyperinsulinism. Metabolism: Clinical and Experimental, 1981, 30, 1001-1010.	3.4	32
209	TRUNCAL VAGOTOMY ABOLISHES THE SOMATOSTATIN RESPONSE TO INSULIN-INDUCED HYPOGLYCEMIA IN MAN. Journal of Clinical Endocrinology and Metabolism, 1981, 52, 823-825.	3.6	34
210	Plasma Human Pancreatic Polypeptide Responses to Administered Secretin: Effects of Surgical Vagotomy, Cholinergic Blockade, and Chronic Pancreatitis*. Journal of Clinical Endocrinology and Metabolism, 1980, 50, 1094-1099.	3.6	80
211	Elevated brain-derived cell-free DNA among patients with first psychotic episode â€“ a proof-of-concept study. ELife, 0, 11, .	6.0	9